Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28113971 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10TP53TSHR | |
| SCHEMBL29433155 | 0.67 | ALOX15 (0.90) | ALDH1A1LMNAHSD17B10KDM4ECA12 | |
| SCHEMBL9015208 | 0.67 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10TSHRTDP1 | |
| SCHEMBL4080987 | 0.65 | CDK4 (0.43) | ALDH1A1LMNACA12HPGDTSHR | |
| SCHEMBL30522768 | 0.65 | CDK4 (0.43) | ALDH1A1LMNACA12HPGDTSHR | |
| SCHEMBL3244128 | 0.64 | — | — | |
| SCHEMBL10333381 | 0.63 | LMNA (0.34) | ALDH1A1LMNAHPGDHSP90AA1RAB9A | |
| SCHEMBL6800419 | 0.63 | L3MBTL1 (0.41) | ALDH1A1LMNAKDM4ETP53MAPT | |
| SCHEMBL7015023 | 0.63 | GAA (0.45) | ALDH1A1LMNAHSD17B10KDM4EMAPT | |
| SCHEMBL29373914 | 0.62 | ALOX15 (0.90) | ALDH1A1LMNAHSD17B10KDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49918-E1 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3666289-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10570212-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3053600-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190263924-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10364294-B2 | Methods of preparation of conjugates | IMMUNOGEN, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| EP-3498303-A1 | METHODS OF PREPARATION OF CONJUGATES | ImmunoGen, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10179818-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-2675480-B1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180037659-A1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN, INC. | 2018-02-08 | — | — | US | disclosed |
| EP-1819687-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | Aventis Pharma S.A. (FR) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| EP-1813614-A1 | Cytotoxic agents comprising new tomaymycin derivatives | Sanofi-Aventis (FR) | 2007-08-01 | — | — | EP | disclosed |
| US-20060178427-A1 | Cytotoxic agents comprising new taxanes | AVENTIS PHARMA S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| WO-2006061258-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061259-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| US-6913748-B2 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1542723-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | Immunogen, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004016801-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179818-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | ALDH1A1 623/4885LMNA 2320/4885HSD17B10 1226/4885 |
| US-10570212-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | ALDH1A1 623/4885LMNA 2320/4885HSD17B10 1226/4885 |
| US-20060178427-A1 | Cytotoxic agents comprising new taxanes | TP53, MCL1, TOP2A | ALDH1A1 2557/4885LMNA 1893/4885HSD17B10 3603/4885 |
| US-20180037659-A1 | METHODS OF PREPARATION OF CONJUGATES | MCL1, EPCAM, PAICS | ALDH1A1 847/4885LMNA 1318/4885HSD17B10 3786/4885 |
| US-10364294-B2 | Methods of preparation of conjugates | MCL1, EPCAM, PAICS | ALDH1A1 847/4885LMNA 1318/4885HSD17B10 3786/4885 |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | CD44, ABCG2, EPCAM | ALDH1A1 1402/4885LMNA 4321/4885HSD17B10 3412/4885 |
| US-20190263924-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | ALDH1A1 623/4885LMNA 2320/4885HSD17B10 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.